Business Description
Enliven Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US29337E1029
Total Employee Number:
61Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1498.02 | |||||
Equity-to-Asset | 0.98 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -30.9 | |||||
3-Year EPS without NRI Growth Rate | -25.9 | |||||
3-Year FCF Growth Rate | -16.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -21.28 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.34 | |||||
9-Day RSI | 58.41 | |||||
14-Day RSI | 59.92 | |||||
3-1 Month Momentum % | 7.95 | |||||
6-1 Month Momentum % | 85.3 | |||||
12-1 Month Momentum % | 117.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 40.32 | |||||
Quick Ratio | 40.32 | |||||
Cash Ratio | 39.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.1 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -22.8 | |||||
ROA % | -22.06 | |||||
ROIC % | -1278.24 | |||||
3-Year ROIIC % | 3832.56 | |||||
ROC (Joel Greenblatt) % | -15723.52 | |||||
ROCE % | -26.72 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.11 | |||||
Price-to-Tangible-Book | 7.11 | |||||
EV-to-EBIT | -28.76 | |||||
EV-to-Forward-EBIT | -7.16 | |||||
EV-to-EBITDA | -28.81 | |||||
EV-to-FCF | -50.77 | |||||
| Price-to-Net-Current-Asset-Value | 7.14 | |||||
| Price-to-Net-Cash | 7.31 | |||||
Earnings Yield (Greenblatt) % | -3.48 | |||||
FCF Yield % | -1.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELVN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enliven Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.67 | ||
| Beta | 0.0949 | ||
| 3-Year Sharpe Ratio | 0.69 | ||
| 3-Year Sortino Ratio | 1.53 | ||
| Volatility % | 87.63 | ||
| 14-Day RSI | 59.92 | ||
| 14-Day ATR ($) | 2.6114 | ||
| 20-Day SMA ($) | 51.4845 | ||
| 12-1 Month Momentum % | 117.63 | ||
| 52-Week Range ($) | 14.785 - 54.88 | ||
| Shares Outstanding (Mil) | 71.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enliven Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enliven Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 18 days | ||
| Guidance call for 2026 | 2026-06-11 08:30 | 37.00 (+3.61%) | ||
| General meeting for 2026 | 2026-06-09 10:00 | 33.63 (-5.13%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 36.03 (+2.18%) | ||
| TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-27 14:30 | 42.53 (+1.17%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 41.20 (-1.86%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 10:30 | 29.50 (+2.29%) | ||
| Annual report for 2025 | 2026-03-03 | 29.50 (+2.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 29.50 (+2.29%) |
Show
Entries
Enliven Therapeutics Inc Frequently Asked Questions
What is Enliven Therapeutics Inc(ELVN)'s stock price today?
The current price of ELVN is $52.95. The 52 week high of ELVN is $54.88 and 52 week low is $14.79.
When is next earnings date of Enliven Therapeutics Inc(ELVN)?
The next earnings date of Enliven Therapeutics Inc(ELVN) is 2026-08-13 Est..
Does Enliven Therapeutics Inc(ELVN) pay dividends? If so, how much?
Enliven Therapeutics Inc(ELVN) does not pay dividend.
Guru Commentaries on NAS:ELVN
No articles.
Press Release
Articles on Enliven Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers